4-(苄氧基)-2-氯喹唑啉 | 100954-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-(苄氧基)-2-氯喹唑啉
• 英文名称: 4-(benzyloxy)-2-chloroquinazoline
• 英文别名: 4-benzyloxy-2-chloro-quinazoline；2-Chlor-4-benzyloxy-chinazolin；2-chloro-4-phenylmethoxyquinazoline
• CAS: 100954-66-3
• 化学式: C₁₅H₁₁ClN₂O
• 分子量: 270.718
• InChiKey: JNPWRHNQAQQAIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(苄氧基)-2-氯喹唑啉 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 叔丁胺 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 以54 %的产率得到4-benzyloxyquinazolin-2-amine
  参考文献：
  名称：

  [EN] PTPN2 INHIBITORS
  [FR] INHIBITEURS DE PTPN2

  摘要：

  The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes (PTPN1 and/or PTPN2) useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I). Further disclosed a method of treating a disease or disorder associated with PTPN1/PTPN2, comprising of administering to a subject a compound or a pharmaceutical composition.

  公开号：

  WO2023220572A1
• 作为产物：
  描述：

  2,4-二氯喹唑啉 、 苯甲醇 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 以78%的产率得到4-(苄氧基)-2-氯喹唑啉
  参考文献：
  名称：

  N 2，N 4-二取代喹唑啉-2,4-二胺类抗SAR精制

  摘要：

  内脏利什曼病是一种被忽视的寄生虫病，在没有治疗的情况下死亡率很高。廉价，口服活性和有效的新药可能是对抗这种疾病的有用工具。我们以前表明，N 2，N 4-二取代的喹唑啉-2,4-二胺对细胞内利什曼原虫和铅化合物N 4-（呋喃-2-基甲基）-N 2-异丙基-7表现出低至亚微摩尔的效价。-甲基喹唑啉-2,4-二胺（4）在内脏利什曼病的急性小鼠模型中显示适度的功效。在本工作中，31 N 2，N评估了以前未检查过抗霉菌活性的4-二取代喹唑啉-2,4-二胺对内脏利什曼病的致病性寄生虫利什曼原虫的效力和选择性。在N 2和N 4处均具有芳族取代基的喹唑啉2,4-二胺显示出有效的体外抗菌活性，但选择性相对较低，而在N 2或N 4处被小烷基取代的化合物通常显示出较低的抗菌活性，但较少对鼠巨噬细胞系有毒。根据他们的体外抗农杆菌效力，N 4选择-苄基-N 2-（4-氯苄基）喹唑啉-2,4-二胺（15）和N 2-苄基-N

  DOI：

  10.1016/j.bmc.2015.02.020

文献信息

• [EN] MTH1 INHIBITORS FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE MTH1 POUR LE TRAITEMENT DE MALADIES
  申请人：BOARD OF REGENTS UNIV OF TEXAS SYSTEM

  公开号：WO2016145383A1

  公开（公告）日：2016-09-15

  Disclosed herein are compounds and compositions having the structure of Formula I, which are useful in the treatment of diseases, such as cancer, where inhibition of MTHl is expected to confer an advantage to a patient. Methods of inhibition of MTHl activity in a human or animal subject are also provided.

  本文披露了具有Formula I结构的化合物和组合物，这些化合物在治疗疾病（如癌症）中非常有用，其中预期抑制MTHl将为患者带来优势。还提供了在人类或动物主体中抑制MTHl活性的方法。
• COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE
  申请人：Chen Li

  公开号：US20130196974A1

  公开（公告）日：2013-08-01

  A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R 1 to R 10 , A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

  一种化合物的公式（I），以及其药学上可接受的盐，其中R1至R10，A，Q，X和Y的定义如规范和索赔中所述，以及其作为药物用于治疗或预防呼吸道合胞病毒疾病的用途。
• Discovery of Quinazolines as Histamine H₄ Receptor Inverse Agonists Using a Scaffold Hopping Approach
  作者：Rogier A. Smits、Iwan J. P. de Esch、Obbe P. Zuiderveld、Joachim Broeker、Kamonchanok Sansuk、Elena Guaita、Gabriella Coruzzi、Maristella Adami、Eric Haaksma、Rob Leurs

  DOI：10.1021/jm800876b

  日期：2008.12.25

  From a series of small fragments that was designed to probe the histamine H-4 receptor (H4R), we previously described quinoxaline-containing fragments that were grown into high affinity H4R ligands in a process that was guided by pharmacophore modeling. With a scaffold hopping exercise and using the same in silico models, we now report the identification and optimization of a series of quinazoline-containing H4R compounds. This approach led to the discovery of 6-chloi-o-N-(furan-3-yl)methyl)2-(4-methylpiperzin-1-yl)quinazolin-4-amine (VUF10499, 54) and 6-chloro-2-(4-methylpiperazin-1-yl)-N-(thiophen-2-ylmethyl)quinazolin-4-amine (VUF10497, 55) as potent human H4R inverse agonists (pK(i) = 8.12 and 7.57, respectively). Interestingly, both compounds also possess considerable affinity for the human histamine Hi receptor (H1R) and therefore represent a novel class of dual action H1R/H4R ligands, a profile that potentially leads to added therapeutic benefit. Compounds from this novel series of quirlazolines are antagonists at the rat H4R and were found to possess anti-inflammatory properties in vivo in the rat.
• US8871756B2
  申请人：——

  公开号：US8871756B2

  公开（公告）日：2014-10-28
• SAR refinement of antileishmanial N2,N4-disubstituted quinazoline-2,4-diamines
  作者：Xiaohua Zhu、Kurt S. Van Horn、Megan M. Barber、Sihyung Yang、Michael Zhuo Wang、Roman Manetsch、Karl A. Werbovetz

  DOI：10.1016/j.bmc.2015.02.020

  日期：2015.8

  previously been examined for their antileishmanial activity were evaluated for their potency and selectivity against Leishmania donovani, the causative parasite of visceral leishmaniasis. Quinazoline-2,4-diamines with aromatic substituents at both N2 and N4 exhibited potent in vitro antileishmanial activity but relatively low selectivity, while compounds substituted with small alkyl groups at either N2

  内脏利什曼病是一种被忽视的寄生虫病，在没有治疗的情况下死亡率很高。廉价，口服活性和有效的新药可能是对抗这种疾病的有用工具。我们以前表明，N 2，N 4-二取代的喹唑啉-2,4-二胺对细胞内利什曼原虫和铅化合物N 4-（呋喃-2-基甲基）-N 2-异丙基-7表现出低至亚微摩尔的效价。-甲基喹唑啉-2,4-二胺（4）在内脏利什曼病的急性小鼠模型中显示适度的功效。在本工作中，31 N 2，N评估了以前未检查过抗霉菌活性的4-二取代喹唑啉-2,4-二胺对内脏利什曼病的致病性寄生虫利什曼原虫的效力和选择性。在N 2和N 4处均具有芳族取代基的喹唑啉2,4-二胺显示出有效的体外抗菌活性，但选择性相对较低，而在N 2或N 4处被小烷基取代的化合物通常显示出较低的抗菌活性，但较少对鼠巨噬细胞系有毒。根据他们的体外抗农杆菌效力，N 4选择-苄基-N 2-（4-氯苄基）喹唑啉-2,4-二胺（15）和N 2-苄基-N